Company & Philosophy
NanoValent Pharmaceuticals, Inc. (NVP), founded in 2006, is a privately-held company focused on new generation ADC (antibody-drug conjugated) based therapy and collaborating closely with the Children’s Hospital Los Angeles (CHLA). NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational team.
NVP is advancing a new generation and targeted nanoparticle based ADC technology (NanoMod™) that may provide a vast improvement in flexibility and choice for patients restricted by current treatment options. Both by repositioning existing therapies as well as optimising the delivery of emerging candidates.
Our current candidate focus is oncology, initially pediatric focused, but it is already clear that the technology can be clearly applied to other oncology challenges as well as areas such as imaging, vaccines, and other non-oncological sectors as resources and opportunities present.